Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

ISS recommends Illumina shareholders to vote against Roche's nominees

Roche released the following statement in response to a report issued by Institutional Shareholder Services recommending that shareholders of Illumina, Inc. vote against the election of Roche's independent director nominees to Illumina's Board of Directors.

From Illumina, Inc. 7 Apr 2012

Study explores link between intraoperative blood loss and pediatric patients' underlying condition

The relative risk of blood loss during corrective spine surgery in children appears linked to the underlying condition causing the spinal deformity, according to a new study from Johns Hopkins Children's Center.

7 Apr 2012

Presage Biosciences enters cancer research agreement with Millennium

Presage Biosciences, a leader in identifying clinically viable oncology drug combinations, today announced that it has entered into a cancer research agreement with Millennium: The Takeda Oncology Company.

7 Apr 2012

Teva's ANDA for Provigil entitled to 180-day exclusivity

Teva Pharmaceutical Industries Ltd. announces that the FDA has decided that its wholly owned subsidiary, Teva Pharmaceuticals USA, is sole first-to-file for both Orange Book patents listed for Provigil (modafinil) and therefore Teva's ANDA alone is entitled to 180-day exclusivity.

6 Apr 2012

Regeneron, Sanofi announce clinical and regulatory update for ZALTRAP

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review of the Biologics License Application (BLA) for the investigational agent ZALTRAP (aflibercept) concentrate for solution for infusion in combination with the irinotecan-fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer (mCRC) previously treated with an oxaliplatin-containing regimen.

6 Apr 2012

TJUH medical oncologist to receive ASCO Humanitarian Award

Edith Mitchell, M.D., FACP, a medical oncologist at Thomas Jefferson University Hospital and Jefferson's Kimmel Cancer Center (KCC) and Clinical Professor of Medicine and Medical Oncology in the Department of Medical Oncology at Jefferson Medical College of Thomas Jefferson University, has been named the 2012 recipient of the American Society of Clinical Oncology (ASCO) Humanitarian Award for her personification of the society's mission and values, and for going above and beyond the call of duty in providing outstanding patient care.

6 Apr 2012

State roundup: Advocates in Va. back shifting disability care from state institutions; New Vt. law overhauls mental health system; Aetna mistakenly tells thousands in Calif. their doctors were dropped

A state agency that looks out for the rights of people with disabilities is advocating for a proposed settlement that would shift the care of Virginians with intellectual disabilities from state-run institutions.

6 Apr 2012

Zalicus' cHTS platform identifies synergistic drug combinations for treatment of cancer

Adenosine A2A and beta-2 adrenergic receptor agonists are highly synergistic and selective novel agents that enhance glucocorticoid activity in B-cell malignancies such as multiple myeloma and, importantly, can synergize in combination with current multiple myeloma treatment regimens such as melphalan, lenalidomide, bortezomib and doxorubicin.

6 Apr 2012

African American women more likely to have ER-negative breast cancer

American women of African ancestry are more likely than European Americans to have estrogen-receptor-negative (ER-negative) breast cancer. There continues to be discussion about the role of low levels of vitamin D in the development of breast cancer for these women.

6 Apr 2012

Spectrum’s apaziquone Phase 3 trials on bladder cancer do not meet primary endpoint

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that the two double blind, randomized, placebo controlled, Phase 3 clinical trials for apaziquone did not meet their primary endpoint of a statistically significant difference in the rate of tumor recurrence at 2 years between the two arms.

6 Apr 2012

Evergreen Healthcare employs transanal endoscopic microsurgery for colorectal tumor removal

Evergreen Healthcare today announced that it has successfully integrated a colorectal procedure called transanal endoscopic microsurgery to its growing suite of minimally invasive surgical options, reducing the need for major surgery and providing patients with faster recovery times.

6 Apr 2012

Spectrum signs definitive agreement to acquire Allos

Spectrum Pharmaceuticals and Allos Therapeutics, Inc. today announced that they have signed a definitive agreement under which Spectrum will acquire all of the outstanding shares of Allos for $1.82 per share in cash plus one Contingent Value Right.

6 Apr 2012

Delcath’s second generation CHEMOSAT system receives European CE Mark

Delcath Systems, Inc. today announced that the Company has received CE Mark approval for the second generation hemofiltration cartridge of the Company's proprietary Hepatic CHEMOSAT Delivery System.

6 Apr 2012

New microfluidics-based microarray can accurately detect breast cancer

One in eight women will be diagnosed with breast cancer during her lifetime. The earlier cancer is detected, the better the chance of successful treatment and long-term survival. However, early cancer diagnosis is still challenging as testing by mammography remains cumbersome, costly, and in many cases, cancer can only be detected at an advanced stage.

6 Apr 2012

Breast cancer screening false positive results may need more follow up: Study

A Danish study of more than 58,000 women found those who had false positive mammograms, meaning the results suggested breast cancer when there was none, had a 67 percent higher risk of developing breast cancer later in life compared with women who had negative mammograms.

5 Apr 2012

Proton beam therapy centers projected for Manchester and London by 2017

A bid to make a £250m project catering “cutting-edge” radiotherapy centers in Manchester and London by 2017 has been confirmed. The plan will see University College London Hospital (UCLH) and The Christie offer proton beam therapy, which uses a particle beam to destroy cancer cells.

5 Apr 2012

Uterine cancer up by 43% in UK over last two decades

Figures show that the number of diagnoses remained static for many years, but has increased by 43% since the 1990s. As the number of womb cancer cases have increased over the last decade, so have the number of womb cancer deaths. However, survival has also improved during that period, with 77% of women who are diagnosed with womb cancer now surviving for five years or more.

5 Apr 2012

Opportunity for developers and marketers of EGFR inhibitors in Brazil and Mexico

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that patient access to premium-priced targeted cancer treatments in Brazil and Mexico is improving, creating an opportunity for developers and marketers of epidermal growth factor receptor (EGFR) inhibitors.

5 Apr 2012

The 31st ESTRO congress and the World Congress of Brachytherapy

ESTRO 31 and the World Congress of Brachytherapy will combine to feature new research results in clinical and basic radiobiology, physics and brachytherapy, presented by top doctors and scientists from all over the world working together for the benefit of cancer patients.

5 Apr 2012

ARI-4175 drug may treat colorectal cancer patients with KRAS mutation

When combined with other treatments, the drug cetuximab-which works by slowing or stopping the growth of cancer cells-has been shown to extend survival in certain types of cancer, including metastatic colorectal cancers. Unfortunately, about 40 percent of colorectal cancer patients-specifically those who carry a mutated form of a gene called KRAS-do not respond to the drug. Researchers at Fox Chase Cancer Center in Philadelphia, however, have been working on a way to overcome this resistance to cetuximab by unleashing a second cetuximab driven mechanism using a novel drug called ARI-4175.

5 Apr 2012